Fox Run Management L.L.C. Buys 13,966 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fox Run Management L.L.C. raised its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 149.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,290 shares of the biopharmaceutical company's stock after acquiring an additional 13,966 shares during the quarter. Fox Run Management L.L.C.'s holdings in Celldex Therapeutics were worth $589,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently modified their holdings of CLDX. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 14.5% in the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock valued at $314,190,000 after buying an additional 1,167,659 shares in the last quarter. Fisher Asset Management LLC lifted its stake in Celldex Therapeutics by 210.6% in the 3rd quarter. Fisher Asset Management LLC now owns 374,352 shares of the biopharmaceutical company's stock worth $12,724,000 after purchasing an additional 253,808 shares in the last quarter. American Century Companies Inc. increased its holdings in shares of Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock worth $15,376,000 after purchasing an additional 193,093 shares during the period. Readystate Asset Management LP purchased a new stake in shares of Celldex Therapeutics in the third quarter worth $6,102,000. Finally, Sovran Advisors LLC bought a new stake in Celldex Therapeutics during the fourth quarter valued at $2,867,000.

Remove Ads

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CLDX. The Goldman Sachs Group dropped their price target on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Celldex Therapeutics in a research note on Friday, February 28th. Cantor Fitzgerald reissued an "overweight" rating and issued a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Morgan Stanley started coverage on shares of Celldex Therapeutics in a report on Thursday, March 20th. They set an "overweight" rating and a $46.00 price objective for the company. Finally, UBS Group started coverage on Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 target price on the stock. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $54.33.

Celldex Therapeutics Trading Down 1.9 %

Shares of NASDAQ:CLDX traded down $0.38 on Wednesday, reaching $19.77. 323,060 shares of the company traded hands, compared to its average volume of 822,481. Celldex Therapeutics, Inc. has a 52 week low of $18.61 and a 52 week high of $47.00. The business's 50-day simple moving average is $22.09 and its 200 day simple moving average is $26.69. The stock has a market capitalization of $1.31 billion, a P/E ratio of -7.69 and a beta of 1.76.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.02. The company had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. Sell-side analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.